Novo Nordisk to slash prices of weightloss drugs in US / Photo: © GETTY IMAGES NORTH AMERICA/AFP/File
JRI
-0.0400
The Fort Worth Press - Novo Nordisk to slash prices of weightloss drugs in US
USD
-
AED 3.673028
AFN 65.499756
ALL 79.240058
AMD 364.469921
ANG 1.789783
AOA 917.999836
ARS 1513.137196
AUD 1.389777
AWG 1.8
AZN 1.69298
BAM 1.680277
BBD 2.014159
BDT 123.275844
BGN 1.696366
BHD 0.37703
BIF 2990
BMD 1
BND 1.27202
BOB 11.57514
BRL 5.165803
BSD 1.000034
BTN 95.488638
BWP 13.399086
BYN 3.015872
BYR 19600
BZD 2.011237
CAD 1.38554
CDF 2274.9995
CHF 0.804345
CLF 0.023451
CLP 923.020282
CNY 6.72275
CNH 6.71984
COP 3167.87
CRC 454.397058
CUC 1
CUP 26.5
CVE 95.049679
CZK 20.737401
DJF 177.719748
DKK 6.41733
DOP 58.274984
DZD 132.880095
EGP 50.271695
ERN 15
ETB 160.590383
EUR 0.858596
FJD 2.191598
FKP 0.735639
GBP 0.735945
GEL 2.604798
GGP 0.735639
GHS 11.194966
GIP 0.735639
GMD 73.518945
GNF 8777.504007
GTQ 7.631607
GYD 209.218609
HKD 7.838985
HNL 26.880144
HRK 6.468402
HTG 130.827552
HUF 313.829501
IDR 17731
ILS 2.96645
IMP 0.735639
INR 95.506197
IQD 1310.5
IRR 1374575.000073
ISK 120.379821
JEP 0.735639
JMD 158.759069
JOD 0.708984
JPY 159.438497
KES 129.439646
KGS 87.449662
KHR 4045.000344
KMF 423.000604
KPW 900.000294
KRW 1382.14004
KWD 0.30855
KYD 0.833362
KZT 462.786202
LAK 22419.99977
LBP 89550.000217
LKR 328.549398
LRD 181.724979
LSL 15.980092
LTL 2.95274
LVL 0.60489
LYD 6.334974
MAD 9.26375
MDL 17.130314
MGA 4334.999888
MKD 52.853823
MMK 2100.008538
MNT 3596.251996
MOP 8.073746
MRU 40.098403
MUR 46.795771
MVR 15.459728
MWK 1735.999641
MXN 16.971203
MYR 4.0327
MZN 63.905032
NAD 15.970192
NGN 1343.630107
NIO 36.719756
NOK 9.323955
NPR 152.781477
NZD 1.68094
OMR 0.3845
PAB 1.000034
PEN 3.350985
PGK 4.428979
PHP 61.933959
PKR 277.550199
PLN 3.72344
PYG 5937.463755
QAR 3.64525
RON 4.514498
RSD 100.67598
RUB 85.935371
RWF 1470
SAR 3.75363
SBD 8.000128
SCR 14.594114
SDG 600.999688
SEK 9.52427
SGD 1.271375
SHP 0.740866
SLE 24.703345
SLL 20969.499227
SOS 571.490866
SRD 37.731977
STD 20697.981008
STN 21.35
SVC 8.750263
SYP 13001.999906
SZL 15.809833
THB 32.887504
TJS 9.225224
TMT 3.51
TND 2.895497
TOP 2.40776
TRY 48.134899
TTD 6.788034
TWD 31.693949
TZS 2647.502955
UAH 44.554757
UGX 3755.235293
UYU 40.198803
UZS 11824.999832
VES 786.285303
VND 26078
VUV 118.45632
WST 2.706367
XAF 563.56115
XAG 0.014453
XAU 0.000217
XCD 2.70255
XCG 1.802311
XDR 0.707052
XOF 562.511908
XPF 102.64961
YER 237.049806
ZAR 16.00577
ZMK 9001.223681
ZMW 19.025568
ZWL 321.999592
- Callaway cuts ties with golf media firm over violent ad
- American Masai Russell sets new women's 100m hurdles world record
- Trump says Putin won't attack NATO territory
- Smith and Cox revive England after Abbas strikes for Pakistan
- Labor Day 2026: Complete Starter Tool Kit Under $375
- Brazil's Alison Dos Santos sets new men's 400m hurdles world record
- Tamil Nadu Govt Assigns Ministers to Oversee Chennai Monsoon Preparedness
- The Nile Theater Announces Full 2026 Concert Lineup Including Menzingers and Shakey Graves
- Alfred gets revenge on Jefferson-Wooden in Zurich 100m
- Venezuelan Artist Oswaldo Vigas Retrospective Opens in Guangzhou
Novo Nordisk to slash prices of weightloss drugs in US
Danish drugmaker Novo Nordisk, which is struggling with competition for its anti-obesity treatments, said Tuesday that it will sharply cut prices for its flagship drugs in the US, announcing a 50 percent cut for Wegovy and 35 percent for Ozempic.
"This decision applies to all doses of these medicines and reflects Novo Nordisk's commitment to enhancing affordability for patients and both public and private payers dealing with the complexities of the evolving US healthcare system," the company said in a statement.
Effective January 1, 2027, the list price will be $675 for a month's worth of Wegovy, which currently costs around $1,350 a month.
Ozempic and Rybelsus, treatments that each currently come to about $1,000, will also be priced $675.
Novo Nordisk said the price reduction is meant to make it possible to reach more patients.
"Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States," Jamey Millar, executive vice president of Novo Nordisk's US Operations, said.
In early February, Novo Nordisk vowed legal against US chain Hims & Hers for offering a copycat of the new pill version of Wegovy.
Limited production capacity for the blockbuster drug led the FDA to temporarily allow pharmacies to create so-called "compound" or copycat versions of Wegovy and Ozempic, an analogue used to treat diabetes.
That authorisation expired last May 22 but Novo Nordisk has complained of copycat versions of its drugs still being available.
Ozempic is an injectable anti-diabetic treatment that became popular on social media for its slimming properties.
Wegovy, which has the same active ingredient as Ozempic in a different dose, is a weight-loss drug and is also available in pill form.
Both treatments use analogues of the hormone GLP-1, which regulates blood glucose levels and appetite.
Shares in Novo Nordisk have taken a beating in recent weeks after it warned in early February of lower sales revenue in the United States as intensified competition pushes down prices.
They fell 3.8 percent in afternoon trading in Copenhagen.
W.Lane--TFWP
